Tan, Tricia

Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia

Tan, T. M., Field, B. C. T., McCullough, K. A., Troke, R. C., Chambers, E. S., Salem, V., Gonzalez Maffe, J., Baynes, K. C. R., De Silva, A., Viardot, A., et al. (2013) · Diabetes

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 258

Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial

Miras, A. D., Pérez-Pevida, B., Aldhwayan, M., Kamocka, A., McGlone, E. R., Al-Najim, W., Chahal, H., Batterham, R. L., McGowan, B., Khan, O., et al. (2019) · The Lancet Diabetes & Endocrinology

Bariatric Surgery and OutcomesDiabetes Treatment and Management

Cited by 190

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

Pollock, K. M., Cheeseman, H. M., Szubert, A. J., Libri, V., Boffito, M., Owen, D., Bern, H., McFarlane, L. R., O'Hara, J., Lemm, N.-M., et al. (2022) · eClinicalMedicine

SARS-CoV-2 and COVID-19 ResearchRNA Interference and Gene Delivery

Cited by 173

Glucagon increases energy expenditure independently of brown adipose tissue activation in humans

Salem, V., Izzi‐Engbeaya, C., Coello, C., Thomas, D. B., Chambers, E. S., Comninos, A. N., Buckley, A., Win, Z., Al‐Nahhas, A., Rabiner, E. A., et al. (2016) · Diabetes, Obesity and Metabolism

Adipose Tissue and MetabolismRegulation of Appetite and Obesity

Cited by 167

Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake

Cegla, J., Troke, R. C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K. A., Lim, C. T., Parvizi, N., Hussein, M., Chambers, E. S., et al. (2014) · Diabetes

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 159

100 years of glucagon and 100 more

Wewer Albrechtsen, N. J., Holst, J. J., Cherrington, A. D., Finan, B., Gluud, L. L., Dean, E. D., Campbell, J. E., Bloom, S. R., Tan, T. M.-M., Knop, F. K., et al. (2023) · Diabetologia

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 117

The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers

Tan, T., Behary, P., Tharakan, G., Minnion, J., Al-Najim, W., Albrechtsen, N. J. W., Holst, J. J., & Bloom, S. R. (2017) · The Journal of Clinical Endocrinology & Metabolism

Regulation of Appetite and ObesityBariatric Surgery and Outcomes

Cited by 88

Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non‐surgical and bariatric surgery patients

Suliman, M., Buckley, A., Al Tikriti, A., Tan, T., le Roux, C. W., Lessan, N., & Barakat, M. (2019) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 86

Striking the balance: GLP-1/glucagon co-agonism as a treatment strategy for obesity

Hope, D. C. D., Vincent, M. L., & Tan, T. M. M. (2021) · Frontiers in Endocrinology

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 81

The Influence of Peptide Context on Signaling and Trafficking of Glucagon-like Peptide-1 Receptor Biased Agonists

Fang, Z., Chen, S., Pickford, P., Broichhagen, J., Hodson, D. J., Corrêa, I. R., Kumar, S., Görlitz, F., Dunsby, C., French, P. M. W., et al. (2020) · ACS Pharmacology & Translational Science

Receptor Mechanisms and SignalingDiabetes Treatment and Management

Cited by 38

Cracking the combination: Gut hormones for the treatment of obesity and diabetes

Alexiadou, K., Anyiam, O., & Tan, T. (2019) · Journal of Neuroendocrinology

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 34

Safety and efficacy of an extended‐release peptide YY analogue for obesity: A randomized, placebo‐controlled, phase 1 trial

Tan, T. M. ‐., Minnion, J., Khoo, B., Ball, L., Malviya, R., Day, E., Fiorentino, F., Brindley, C., Bush, J., & Bloom, S. R. (2021) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 34

Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss

Hope, D. C. D., Hinds, C. E., Lopes, T., Vincent, M. L., Shrewsbury, J. V., Yu, A. T. C., Davies, I., Scott, R., Jones, B., Murphy, K. G., et al. (2022) · Cell Reports Medicine

Regulation of Appetite and ObesityPharmacology and Obesity Treatment

Cited by 32

The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action

Alexiadou, K., Hartley, A., Tan, T. M.-M., & Khamis, R. (2024) · Trends in Cardiovascular Medicine

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 31

Late-night salivary cortisol and cortisone should be the initial screening test for cushing's syndrome

Mohamed, R. S., Abuelgasim, B., Barker, S., Prabhudev, H., Martin, N. M., Meeran, K., Williams, E. L., Darch, S., Matthew, W., Tan, T., et al. (2022) · Endocrine Connections

Pituitary Gland Disorders and TreatmentsAdrenal Hormones and Disorders

Cited by 18

Glucagon and energy expenditure; Revisiting amino acid metabolism and implications for weight loss therapy

Hope, D. C. D., & Tan, T. M.-M. (2023) · Peptides

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 16